MAPT and Alzheimer disease: We applied the platform to human brains (AD vs ND), iPSC-derived neurons (APP duplication vs WT), transgenic mouse brains (PS19 vs WT), and cellular models of human tau toxicity (N2a cells overexpressing human tau vs N2a cells with vector only) (Fig. 3a).